{
  "main_header": {
    "sid": 290229,
    "name": "Zydus Lifesci.",
    "stock_name": "Zydus Lifesci.",
    "full_name": "Zydus Lifesciences Ltd",
    "name_url": "stocks-analysis/zydus-lifesci",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "911.90",
    "chg": -5.55,
    "chgp": "-0.6%",
    "dir": -1,
    "prev_price": "917.45",
    "mcapval": "91,758.48 Cr",
    "mcap": "Large Cap",
    "scripcode": 532321,
    "symbol": "ZYDUSLIFE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE010B01027",
    "curr_date": "Dec 26",
    "curr_time": "",
    "bse_nse_vol": "77.99 k",
    "exc_status": "Active",
    "traded_date": "Dec 26, 2025",
    "traded_date_str": "2025 12 26",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zydus-lifesci-290229-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Zydus Lifesciences Sees Notable Surge in Derivatives Open Interest Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-sharp-open-interest-surge-amid-mixed-market-signals-3768290",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ZydusLifescienc_oi_spurts_by_underlying_3768290.png",
        "date": "2025-12-24 15:00:09",
        "description": "Zydus Lifesciences Ltd has registered a significant rise in open interest within its derivatives segment, reflecting evolving market positioning despite a subdued performance in the underlying equity. This development comes amid a backdrop of falling investor participation and mixed technical indicators, prompting closer scrutiny of the stock’s near-term directional bets."
      },
      {
        "title": "Zydus Lifesciences Sees Notable Surge in Derivatives Open Interest Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-sharp-open-interest-surge-amid-mixed-market-signals-3768243",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ZydusLifescienc_oi_spurts_by_underlying_3768243.png",
        "date": "2025-12-24 14:00:09",
        "description": "Zydus Lifesciences Ltd has registered a significant rise in open interest within its derivatives segment, signalling a shift in market positioning as investors recalibrate their exposure amid subdued price movement and sectoral pressures. The pharmaceutical giant’s derivatives activity reveals evolving sentiment that may influence near-term directional trends."
      },
      {
        "title": "Zydus Lifesciences Sees Notable Surge in Derivatives Open Interest Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-notable-surge-in-derivatives-open-interest-amid-mixed-market-signals-3768201",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ZydusLifescienc_oi_spurts_by_underlying_3768201.png",
        "date": "2025-12-24 13:00:08",
        "description": "Zydus Lifesciences Ltd has experienced a significant rise in open interest within its derivatives segment, reflecting heightened market activity and evolving investor positioning. This development comes amid subdued price movement and a backdrop of cautious investor participation, offering insights into potential directional bets and market sentiment within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Zydus Lifesci. Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zydus-lifesci-downgraded-to-sell-by-marketsmojo-amid-declining-financial-trends-3767096",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ZydusLifesci_mojoScore_3767096.png",
        "date": "2025-12-23 10:10:03",
        "description": "Zydus Lifesci., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, signalling a more cautious stance from market analysts."
      },
      {
        "title": "Zydus Lifesciences Evaluation Revised Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zydus-lifesciences-downgraded-to-sell-amid-technical-weakness-and-financial-concerns-3740605",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ZydusLifescienc_mojoScore_3740605.png",
        "date": "2025-12-02 08:32:00",
        "description": "Zydus Lifesciences, a prominent player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market assessment following a detailed analysis of its financial performance, valuation metrics, technical indicators, and overall quality parameters. This article explores the factors influencing the recent shift in the company's evaluation, providing investors with a comprehensive understanding of the underlying data driving these changes."
      },
      {
        "title": "Is Zydus Lifesci. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zydus-lifesci-technically-bullish-or-bearish-3740010",
        "imagepath": "",
        "date": "2025-12-02 08:26:29",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Overview</strong></p>\n<p>The latest technical assessment for Zydus Lifesci. shows a transition from a mildly bullish to a mildly bearish trend. This shift is significant as it reflects a change in market sentiment and momentum. The weekly and monthly charts provide a mixed but predominantly bearish picture, with key momentum indicators signalling caution.</p>\n<p>Specifically, the Moving Average Convergence Divergence (MACD) indicator is bearish on the weekly chart and mildly bearish on the monthly chart. This suggests that the stock’s momentum is weakening over both short and medium terms. Meanwhile, the Relative Strength Index (RSI) does not currently provide a clear signal on either timeframe, indicating a lack of strong directional momentum.</p>\n<p><strong>Price Volatility..."
      },
      {
        "title": "Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-technical-momentum-shifts-amid-mixed-market-signals-3739938",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ZydusLifescienc_technicaldot_3739938.png",
        "date": "2025-12-02 08:03:23",
        "description": "Zydus Lifesciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish indicators across multiple timeframes. The pharmaceutical and biotechnology company’s stock price movements and technical parameters suggest a nuanced market assessment as it navigates recent evaluation adjustments."
      },
      {
        "title": "How has been the historical performance of Zydus Lifesci.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-zydus-lifesci-3739253",
        "imagepath": "",
        "date": "2025-12-01 23:13:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Growth</strong></p>\n<p>Over the seven-year period ending March 2025, Zydus Lifesci. has steadily expanded its net sales from ₹13,165.6 crores in 2019 to ₹23,241.5 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 11.5%, reflecting the company’s successful market penetration and product portfolio expansion. The total operating income mirrors this trend, with no other operating income reported, indicating that core business activities drive revenue growth.</p>\n<p>Operating profit (PBDIT) excluding other income rose significantly from ₹2,983.5 crores in 2019 to ₹7,058.5 crores in 2025, with the operating profit margin improving from 23.4% to 31.3%. This margin expansion suggests enhanced operational efficiency and cost management. Profit af..."
      },
      {
        "title": "Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-technical-momentum-shifts-amid-mixed-indicator-signals-3734569",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZydusLifescienc_technicaldot_3734569.png",
        "date": "2025-11-28 08:01:20",
        "description": "Zydus Lifesciences has exhibited a nuanced shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This development comes amid a complex array of technical indicator signals, reflecting a blend of cautious optimism and underlying bearish pressures within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 581,
    "sid": "290229",
    "stock_news_url": "https://www.marketsmojo.com/news/zydus-lifesciences-290229"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Updates on Acquisition",
      "datetime": "24-Dec-2025",
      "details": "Update on acquisition of API business",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "23-Dec-2025",
      "details": "Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO an Interchangeable Biosimilar to Lucentis. NUFYMCO BLA has been approved by the USFDA.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "19-Dec-2025",
      "details": "Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has declared <strong>1100%</strong> dividend, ex-date: 25 Jul 25",
          "dt": "2025-07-25",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has announced <strong>1:5</strong> stock split, ex-date: 06 Oct 15",
          "dt": "2015-10-06",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has announced <strong>1:2</strong> bonus issue, ex-date: 05 Apr 10",
          "dt": "2010-04-05",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Zydus Lifesciences Sees Notable Surge in Derivatives Open Interest Amid Mixed Market Signals

2025-12-24 15:00:09

Zydus Lifesciences Ltd has registered a significant rise in open interest within its derivatives segment, reflecting evolving market positioning despite a subdued performance in the underlying equity. This development comes amid a backdrop of falling investor participation and mixed technical indicators, prompting closer scrutiny of the stock’s near-term directional bets.

Read More

Zydus Lifesciences Sees Notable Surge in Derivatives Open Interest Amid Market Volatility

2025-12-24 14:00:09

Zydus Lifesciences Ltd has registered a significant rise in open interest within its derivatives segment, signalling a shift in market positioning as investors recalibrate their exposure amid subdued price movement and sectoral pressures. The pharmaceutical giant’s derivatives activity reveals evolving sentiment that may influence near-term directional trends.

Read More

Zydus Lifesciences Sees Notable Surge in Derivatives Open Interest Amid Market Volatility

2025-12-24 13:00:08

Zydus Lifesciences Ltd has experienced a significant rise in open interest within its derivatives segment, reflecting heightened market activity and evolving investor positioning. This development comes amid subdued price movement and a backdrop of cautious investor participation, offering insights into potential directional bets and market sentiment within the Pharmaceuticals & Biotechnology sector.

Read More

Zydus Lifesci. Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-23 10:10:03

Zydus Lifesci., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, signalling a more cautious stance from market analysts.

Read More

Zydus Lifesciences Evaluation Revised Amid Mixed Financial and Technical Signals

2025-12-02 08:32:00

Zydus Lifesciences, a prominent player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market assessment following a detailed analysis of its financial performance, valuation metrics, technical indicators, and overall quality parameters. This article explores the factors influencing the recent shift in the company's evaluation, providing investors with a comprehensive understanding of the underlying data driving these changes.

Read More

Is Zydus Lifesci. technically bullish or bearish?

2025-12-02 08:26:29

Technical Trend Overview

The latest technical assessment for Zydus Lifesci. shows a transition from a mildly bullish to a mildly bearish trend. This shift is significant as it reflects a change in market sentiment and momentum. The weekly and monthly charts provide a mixed but predominantly bearish picture, with key momentum indicators signalling caution.

Specifically, the Moving Average Convergence Divergence (MACD) indicator is bearish on the weekly chart and mildly bearish on the monthly chart. This suggests that the stock’s momentum is weakening over both short and medium terms. Meanwhile, the Relative Strength Index (RSI) does not currently provide a clear signal on either timeframe, indicating a lack of strong directional momentum.

Price Volatility...

Read More

Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:03:23

Zydus Lifesciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish indicators across multiple timeframes. The pharmaceutical and biotechnology company’s stock price movements and technical parameters suggest a nuanced market assessment as it navigates recent evaluation adjustments.

Read More

How has been the historical performance of Zydus Lifesci.?

2025-12-01 23:13:49

Revenue and Profit Growth

Over the seven-year period ending March 2025, Zydus Lifesci. has steadily expanded its net sales from ₹13,165.6 crores in 2019 to ₹23,241.5 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 11.5%, reflecting the company’s successful market penetration and product portfolio expansion. The total operating income mirrors this trend, with no other operating income reported, indicating that core business activities drive revenue growth.

Operating profit (PBDIT) excluding other income rose significantly from ₹2,983.5 crores in 2019 to ₹7,058.5 crores in 2025, with the operating profit margin improving from 23.4% to 31.3%. This margin expansion suggests enhanced operational efficiency and cost management. Profit af...

Read More

Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals

2025-11-28 08:01:20

Zydus Lifesciences has exhibited a nuanced shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This development comes amid a complex array of technical indicator signals, reflecting a blend of cautious optimism and underlying bearish pressures within the Pharmaceuticals & Biotechnology sector.

Read More

View All News